Genesee Valley Trust’s ResMed RMD Stock Holding History

Genesee Valley Trust’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$446K	Sell	4,685 -70	-1%	-$6.62K	0.18%	92
2017 Q4	$403K	Sell	4,755 -197	-4%	-$16.3K	0.17%	110
2017 Q3	$381K	Buy	4,952 +9	+0.2%	+$688	0.16%	113
2017 Q2	$385K	Sell	4,943 -585	-11%	-$41.9K	0.16%	108
2017 Q1	$397	Buy	5,528 +91	+2%	+$6.29K	0.27%	102
2016 Q4	$337	Buy	5,437 +1,074	+25%	+$65.8K	0.24%	128
2016 Q3	$283K	Buy	+4,363	New	+$290K	0.17%	192

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Genesee Valley Trust's RMD Position: Q1 2018 in Review

Genesee Valley Trust reduced its ResMed (RMD) stake by 1.5% in Q1 2018, selling an estimated $6.62K and leaving 4,685 shares worth $446K. The position accounts for 0.18% of the portfolio, ranked #92.

Genesee Valley Trust first reported a position in RMD in Q3 2016 and has held it in 7 quarters since. 445 funds tracked by Wall St. Rank hold RMD as of Q1 2018.

Genesee Valley Trust held 4,685 shares of ResMed worth $446K as of Q1 2018.
Genesee Valley Trust sold 70 ResMed shares in Q1 2018, an estimated $6.62K.
ResMed made up 0.18% of Genesee Valley Trust's portfolio in Q1 2018, its #92 holding.
Genesee Valley Trust first reported a position in ResMed in Q3 2016 and has held it in 7 quarters since.
445 funds tracked by Wall St. Rank held ResMed as of Q1 2018.

Based on Genesee Valley Trust's 13F filing for Q1 2018, filed 3 Apr 2018.